文献速递肝病消化道肿瘤与早癌

联合使用CLivD评分与FIB-4预测人群中的肝脏相关结局

Combined use of the CLivD score and FIB-4 for prediction of liver-related outcomes in the population.
PubMed 文献 · Hepatology · 2023-12-19

在UK Biobank队列的369,832名基线无肝病成人中外部验证慢性肝病(CLivD)评分预测肝脏相关结局(LROs),并探讨CLivD与纤维化-4(FIB-4)序贯联合使用。10年随访时,CLivD lab(含γ-谷氨酰转移酶)预测LRO的AUC为0.80,CLivD non-lab为0.72,FIB-4为0.75。FIB-4预测性能随CLivD评分升高而提升;联合使用可识别出10年内每3人中约1人发生LRO的高危亚组。

要点

  • CLivD评分是LRO风险评定的有效工具,可提升FIB-4的预测性能。
  • 10年随访时,CLivD lab预测LRO的AUC为0.80,高于FIB-4的0.75和CLivD non-lab的0.72。
  • CLivD与FIB-4联合可识别10年内约1/3个体发生LRO的高危亚组。

核心结论

  • CLivD评分是LRO风险评定的有效工具,并提高FIB-4的预测性能。
  • CLivD与FIB-4联合使用识别出一个亚组,其中每3人中有1人在10年内发生LRO。

研究设计与样本

  • 在UK Biobank队列中外部验证CLivD评分对LRO的预测,并研究CLivD与FIB-4序贯联合使用。
  • 分析纳入369,832名基线无肝病且具备CLivD与FIB-4计算数据的成人。
  • LRO包括代偿或失代偿性肝硬化或HCC,通过电子健康登记链接确认。
  • 采用竞争风险方法评估判别性能和累积发病率。

主要发现

  • 10年随访时,预测LRO的时间依赖AUC:CLivD lab为0.80,CLivD non-lab为0.72,FIB-4为0.75。
  • CLivD lab对肝脏相关死亡和严重酒精相关性肝脏结局的AUC超过0.85。
  • FIB-4的预测性能随CLivD评分升高而提升;10年FIB-4 AUC从CLivD极小风险亚组的0.60升至CLivD高风险亚组的0.81。
  • 在CLivD极小风险亚组中,LRO累积发病率在FIB-4低至高分层间为0.05%至0.3%。
  • 在CLivD高风险亚组中,相应发病率为1.7%至21.1%,FIB-4>3.25者达33%。

关键数值与推荐

  • CLivD lab(含γ-谷氨酰转移酶)10年预测LRO的AUC为0.80。
  • CLivD non-lab(不含实验室值)10年预测LRO的AUC为0.72。
  • FIB-4 10年预测LRO的AUC为0.75。
  • CLivD高风险亚组中FIB-4>3.25者10年LRO累积发病率为33%。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: A need exists for effective and practical tools to identify individuals at increased risk of liver-related outcomes (LROs) within the general population. APPROACH AND RESULTS: We externally validated the chronic liver disease (CLivD) score for LROs in the UK Biobank cohort. We also investigated the sequential combined use of CLivD and fibrosis-4 (FIB-4) scores. Our analysis included 369,832 adults without baseline liver disease and with available data for CLivD and FIB-4 computation. LROs reflecting compensated or decompensated liver cirrhosis or HCC were ascertained through linkages with electronic health care registries. Discriminatory performance and cumulative incidence were evaluated with competing-risk methodologies. Over a 10-year follow-up, time-dependent AUC values for LRO prediction were 0.80 for CLivD lab (including gamma-glutamyltransferase), 0.72 for CLivD non-lab (excluding laboratory values), and 0.75 for FIB-4. CLivD lab demonstrated AUC values exceeding 0.85 for liver-related death and severe alcohol-associated liver outcomes. The predictive performance of FIB-4 increased with rising CLivD scores; 10-year FIB-4 AUC values ranged from 0.60 within the minimal-risk CLivD subgroup to 0.81 within the high-risk CLivD subgroup. Moreover, in the minimal-risk CLivD subgroup, the cumulative incidence of LRO varied from 0.05% to 0.3% across low-to-high FIB-4 strata. In contrast, within the high-risk CLivD subgroup, the corresponding incidence ranged from 1.7% to 21.1% (up to 33% in individuals with FIB-4 >3.25). CONCLUSIONS: The CLivD score is a valid tool for LRO risk assessment and improves the predictive performance of FIB-4. The combined use of CLivD and FIB-4 identified a subgroup where 1 in 3 individuals developed LROs within 10 years.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Åberg F, Asteljoki J, Männistö V, et al. Combined use of the CLivD score and FIB-4 for prediction of liver-related outcomes in the population. Hepatology. 2023. PMID: 38112489. doi:10.1097/HEP.0000000000000707

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。